CJC-1295: separating the mechanism from the hype

A small peptide with a long half-life — and a longer list of overstatements online.

TL;DR

• CJC-1295 is a GHRH analog — a copy of the brain signal that asks the pituitary to release the body’s own growth hormone.
• It does not contain growth hormone, and it is not the same as HGH.
• The mechanism is well-described in the literature. Outcomes depend on the protocol, the clinician, and the patient — not on the peptide name alone.

What it is

CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone (GHRH, in plain English: the brain’s natural “make more growth hormone” signal). Two forms exist. CJC-1295 with DAC carries a drug affinity complex — a tag that lets it persist in the blood for days. CJC-1295 without DAC, sometimes called “Mod GRF 1-29,” clears in minutes. Both ask the same pituitary door to open. The difference is how long the request lingers.

How it works

Think of GHRH as the brain telling the pituitary, “Release a growth-hormone pulse now.” CJC-1295 is a longer-lasting copy of that note. Without DAC, the note is read once and disposed of, so each dose triggers a short, natural pulse (Walker et al., 2006). With DAC, the note hangs on the pituitary’s bulletin board for days, smoothing growth-hormone release across that window. Neither version replaces growth hormone — both depend on the pituitary being able to respond.

Who asks about it

People come to this topic when they see CJC-1295 listed beside HGH and want to know if it is the same thing (it is not). Others come from forum discussions where dosing claims are far above the published clinical literature, and they want a calmer reference point.

What the research says

Human studies of GHRH analogs, including CJC-1295, show a dose-dependent increase in IGF-1 (insulin-like growth factor 1, a downstream marker of growth-hormone activity) when paired with a GHRP such as ipamorelin. Effect sizes on body composition and sleep architecture in supervised protocols are modest and measured in months, not weeks. CJC-1295 with DAC has been studied less in long-duration human trials than its sermorelin cousin — a reason to be honest about the limits of the evidence base.

What to know before considering it

CJC-1295 is generally well-tolerated in physician-supervised protocols. Common reported effects include injection-site reactions, a brief head-rush flush, vivid dreams, and water retention. It requires a valid prescription and clinician evaluation. Compounded versions are prepared by state-licensed 503A pharmacies and are not FDA-approved as finished drugs.

The Halftime POV

The peptide world is not short on hype. CJC-1295 is a well-described tool with real but modest effects in the published literature. We would rather under-promise the mechanism than oversell the marketing.

Related reading:

• CJC-1295 vs sermorelin: comparing two GHRH analogs
• The classic peptide combination: why CJC-1295 and ipamorelin work better together
• Sermorelin, CJC-1295, ipamorelin, MK-677: a plain-language comparison

FAQ

Q: Is CJC-1295 the same as growth hormone? A: No. CJC-1295 is a copy of the brain signal that tells the pituitary to release the body’s own growth hormone. It does not replace growth hormone.

Q: What does the “DAC” in CJC-1295 with DAC mean? A: DAC stands for drug affinity complex. It is a small chemical tag that helps the peptide stick around in the bloodstream longer, so it is dosed less often.

Q: Is CJC-1295 FDA-approved? A: No. CJC-1295 is not FDA-approved as a finished drug. Compounded versions are prepared by state-licensed 503A pharmacies and are not themselves FDA-approved.

Q: What are common reported side effects? A: Injection-site reactions, a temporary head-rush flush, vivid dreams, and water retention are the most commonly reported. Any peptide use should be under physician supervision.

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• Walker RF et al., “Growth hormone-releasing peptides,” Endocr Rev (2006)
• Endocrine Society, “Growth hormone use in adults”

This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health’s published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.